# A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)

> **NCT02230566** · PHASE3 · COMPLETED · sponsor: **Ultragenyx Pharmaceutical Inc** · enrollment: 12 (actual)

## Conditions studied

- MPS 7
- Sly Syndrome
- Mucopolysaccharidosis
- MPS VII

## Interventions

- **DRUG:** UX003
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02230566
- **Lead sponsor:** Ultragenyx Pharmaceutical Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2020-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02230566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02230566, "A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02230566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*